GlassScriptPhysician profile
Hooman MD Poor
NPI 1982863502
$33,322.85
in general payments reported to CMS, 2019-2025
9 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.91 · 2020: $225 · 2021: $5,384 · 2022: $15K · 2023: $5,968 · 2024: $7,007 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $2,176 · Food and Beverage: $276 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,700.00 |
| Travel and Lodging | $2,176.44 |
| Food and Beverage | $276.38 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $12,755.87 | 2020-2023 | Tyvaso |
| Vertex Pharmaceuticals Incorporated | $9,405.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $7,416.68 | 2023-2024 | Winrevair |
| Vivus LLC | $2,570.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $557.59 | 2020-2025 | |
| Baxter Healthcare | $550.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $35.60 | 2023 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $31.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hooman Poor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.